Naile Koleci, Ph.D.’s Post

Uveal melanoma is the most common primary intraocular cancer in adults. Published in the International Journal of Molecular Science (MDPI), Dr. Jesse Berry, member of the USC Norris Epigenetic Regulation in Cancer Program, discovered that the aqueous humor can serve as a liquid biopsy for uveal melanoma. This paper continues the conversation on the role and potential clinical utility of this liquid biopsy platform for ocular cancers. Read the full publication here: https://lnkd.in/gtKTwtzC.

My immense pleasure to present evolving practice changing clinical cases in colorectal cancer at the Annual GI Cancer Symposium at Banner MDAnderson. Thank you Madappa Kundranda MD, PhD for organizing such a great and clinical GI symposium! Key points: - role of ctDNA in stage II colon cancer: DYNAMIC AND CIRCULATE-JAPAN study - d-MMR in locally advanced rectal cancer: Landmark Dostarlimab trial with 100% CCR - EGFRi Panitumumab regardless of sidedness (Left or Right) with OS benefit: PARADIGM study

RESEARCH CALL OUT--last chance for now! Did you develop a second cancer AFTER being diagnosed with #ocularmelanoma? "PURPOSE OF THIS STUDY: The way someone thinks about themselves and their body can change almost immediately after getting a cancer diagnosis. This study is gathering information about the experience of having had an ocular melanoma (OM) cancer, going into remission/cure, and then developing a second non-OM cancer. Part 1 of this study is a recorded virtual interview using ZOOM lasting approximately 20 to 60 minutes. An optional Part 2 of this study is a virtual participant Focus Group moderated by the principal investigator." Find out more at https://lnkd.in/gbPMhyg4 Participants must be 18+ years of age in USA or CA. Contact Jennifer Stephens MA, PhD, RN, OCN, CCNE of the University of Wyoming at jsteph35@uwyo.edu

There is growing evidence showing pelvic high-grade serous carcinoma (the most common type of ovarian cancer) develops from the fallopian tube epithelium through sequential stages of precursor lesions. A better understanding of these lesions is critical for the development of improved diagnostic strategies. In our just published study, we characterize the molecular landscape and introduce a method to classify these lesions. Our approach works in as little as a few pg of DNA and offers a highly reproducible adjunct technique to aid in diagnosis. Read the full manuscript: https://lnkd.in/e_z6eJrg

In the future, ovarian cancer could be diagnosed with a blood test signaling the probability of its occurrence, much like a cholesterol test helps calculate the risk of having a heart attack. The plan is to use the metabolic profiling approach in a large-scale study next year that will enroll high-risk women, and it could also be applicable to triple-negative breast cancer and prostate cancer, report Georgia Tech scientists John McDonald and Jeffrey Skolnick. #ovariancancer #metabolites #diagnostic https://lnkd.in/egdupV4P

https://lnkd.in/drd9-NsJ One of the advantages to rethinking screening is to come up with a better way to manage what's found at the time of screening, including the diagnosis of DCIS. (Or even Gleason 6 prostate cancer!) These are opportunities to re-cast a diagnosis in terms of whether or not someone's risk is elevated and whether or not something is warranted to reduce that risk. The RECAST study for DCIS is now opening across the country. The first two sites are Wake Forest and UCSF!(https://lnkd.in/dByxK_iF)